Pinetree Therapeutics, a preclinical-stage biotechnology company pioneering targeted protein degraders for drug-resistant cancers, announced the successful closing of an oversubscribed $47 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback